A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).
Cynthia X. Ma
No relevant relationships to disclose
Feng Gao
No relevant relationships to disclose
Michael Naughton
No relevant relationships to disclose
Timothy J. Pluard
No relevant relationships to disclose
Steven Sorscher
No relevant relationships to disclose
Allison N Creekmore
No relevant relationships to disclose
Zhanfang Guo
No relevant relationships to disclose
Farrokh Dehdashti
No relevant relationships to disclose
Ben Ho Park
No relevant relationships to disclose
Albert C. Lockhart
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
Matthew J. Ellis
No relevant relationships to disclose
Bracha Erlanger
No relevant relationships to disclose